Becton Dickinson Korea (BD Korea) said on Wednesday that it signed a tripartite strategic memorandum of understanding with BD Global and Celltrion Pharm on Tuesday at the latter’s research institute in Songdo, Incheon, for contract manufacturing organization (CMO) cooperation on prefilled syringes (PFS).

The agreement was actively pursued through BD's CMO Partnership Program, the company added.

Through this agreement, the three companies plan to collaborate by connecting and guiding business opportunities forpharmaceutical companies requiring PFS CMO services, leveraging BD's global syringe customer network and Celltrion Pharm's production capabilities

BD Korea, BD Global, and Celltrion Pharm signed a tripartite strategic business agreement for prefilled syringe (PFS)contract manufacturing (CMO) cooperation at Celltrion Pharm's research institute in Songdo, Incheon, on Tuesday. (Courtesy of BD Korea)
BD Korea, BD Global, and Celltrion Pharm signed a tripartite strategic business agreement for prefilled syringe (PFS)contract manufacturing (CMO) cooperation at Celltrion Pharm's research institute in Songdo, Incheon, on Tuesday. (Courtesy of BD Korea)

They also plan to support pharmaceutical companies by establishing an ecosystem-based partnership program, which includes testing services and sample provision through BD's Greater Asia Integrated Technology Center (BD GAITC), located in Suzhou, China.

Prefilled syringes, which are delivered with medication already filled, were first launched by BD in 1954. They are widely used across various fields and are recognized for enhancing safety and efficiency in healthcare settings.

Twenty-seven of the top 30 global pharmaceutical companies are key BD customers, and BD produced over 3 billion prefilled syringes in fiscal year 2024.

“BD Korea, as a global leader in medical devices and equipment manufacturing, is fostering an innovative pharmaceutical development ecosystem with its partners,” BD Asia Vice President Jeffrey Chen said. “Through this agreement with Celltrion Pharm, we will actively support pharmaceutical companies requiring PFS CMO services by providing stable CMO services and helping them secure global competitiveness.”

Celltrion Pharm CEO Yoo Young-ho remarked, “This agreement will serve as a pivotal turning point for expanding our PFS CMO business into the global market by leveraging BD's worldwide customer network. We will continuously enhance Celltrion Pharm's distinctive PFS production capabilities while strengthening our global CMO business competitiveness to further accelerate the acquisition of new customers.”

Jason Huang, Executive Vice President of BD Asia, also attended the signing ceremony.

Copyright © KBR Unauthorized reproduction, redistribution prohibited